Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

References

• CantiniFNiccoliLNanniniCKaloudiOBertoniMCassaràEPsoriatic arthritis: a systematic reviewInt J Rheum Dis201013430031721199465
   PubMed Web of Science ®Google Scholar
• KammerGMSoterNAGibsonDJSchurPHPsoriatic arthritis: a clinical, immunologic and HLA study of 100 patientsSemin Arthritis Rheum1979927597392764
   PubMed Web of Science ®Google Scholar
• RitchlinCTKavanaughAGladmanDDTreatment recommendations for psoriatic arthritisAnn Rheum Dis20096891387139418952643
   PubMed Web of Science ®Google Scholar
• SalvaraniCPipitoneNMarchesoniARecommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for RheumatologyClin Exp Rheumatol2011293 Suppl 66S28S4121906425
   PubMed Web of Science ®Google Scholar
• MeasePJGoffeBSMetzJEtanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialLancet2000356922738539010972371
   PubMed Web of Science ®Google Scholar
• AntoniCEKavanaughAKirkhamBSustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Arthritis Rheum20055241227123615818699
   PubMed Web of Science ®Google Scholar
• MeasePJGladmanDDRitchlinCTAdalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialArthritis Rheum200552103279328916200601
   PubMed Web of Science ®Google Scholar
• KavanaughAMcInnesIMeasePGolimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled studyArthritis Rheum200960497698619333944
   PubMed Web of Science ®Google Scholar
• GladmanDDMeasePJRitchlinCTAdalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trialArthritis Rheum200756247648817265483
   PubMed Web of Science ®Google Scholar
• MeasePJOryPSharpJTAdalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)Ann Rheum Dis200968570270918684743
   PubMed Web of Science ®Google Scholar
• TaylorWJGladmanDHelliwellPClassification Criteria for Psoriatic Arthritis. Development of New Criteria From a Large International StudyArthritis Rheum20065482665267316871531
   PubMed Web of Science ®Google Scholar
• ArnettFCEdworthySMBlochDAThe American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritisArthritis Rheum19883133153243358796
   PubMed Web of Science ®Google Scholar
• Van der LindenSValkenburgHACatsAEvaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteriaArthritis Rheum19842743613686231933
   PubMed Web of Science ®Google Scholar
• Heuft-DorenboschLSpoorenbergAvan TubergenAAssessment of enthesitis in ankylosing spondylitisAnn Rheum Dis200362212713212525381
   PubMed Web of Science ®Google Scholar
• CalinAportaJFriesJFSchurmanDJClinical history as a screening test for ankylosing spondylitisJAMA19772372426132614140252
   PubMed Web of Science ®Google Scholar
• CantiniFNiccoliLNanniniCFrequency and duration of clinical remission in patients with peripheral arthritis requiring second-line drugsRheumatology (Oxford)200847687287618400836
   PubMed Web of Science ®Google Scholar
• GarrettSIenkinsonTKennedyGWhitelockHGaisfordPCalinAA new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity indexJ Rheumatol19942112228622917699630
   PubMed Web of Science ®Google Scholar
• FransenJCreemersMCVan RielPLRemission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteriaRheumatology (Oxford)200443101252125515238643
   PubMed Web of Science ®Google Scholar
• FredrikssonTPetterssonUSevere psoriasis – oral therapy with a new retinoidDermatologica19781574238244357213
   PubMedGoogle Scholar
• KaneDStaffordLBresnihanBFitzgeraldOA prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experienceRheumatology (Oxford)200342121460146814523223
   PubMed Web of Science ®Google Scholar
• GladmanDDTung HingENGSchentagCTCookRJRemission in Psoriatic arthritisJ Rheumatol20012851045104811361187
   PubMed Web of Science ®Google Scholar
• SaberTPNgCTRenardGRemission in psoriatic arthritis: is it possible and how can it be predicted?Arthritis Res Ther2010123R9420482783
   PubMed Web of Science ®Google Scholar
• SaadAAAshcroftDMWatsonKDSymmonsDPMNoycePRHyrichKLEfficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics RegisterRheumatology201049469770520056769
   PubMed Web of Science ®Google Scholar
• GenoveseMCMeasePJThomsonGTSafety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapyJ Rheumatol20073451040105017444593
   PubMed Web of Science ®Google Scholar
• Van den BoschFMangerBGoupillePEffectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesionsAnn Rheum Dis201069239439919815494
   PubMed Web of Science ®Google Scholar
• AttenoMPelusoRCostaLComparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugsClin Rheumatol201029439940320066450
   PubMed Web of Science ®Google Scholar
• GladmanDDACCLAIM Study InvestigatorsSampalisJSIllouzOGuéretteBResponses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label studyJ Rheumatol20103791898190620595284
   PubMed Web of Science ®Google Scholar
• ScarpaRAttenoMLubranoEThe effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot studyClin Rheumatol20113081063106721360007
   PubMed Web of Science ®Google Scholar
• NawataMSaitoKNakayamadaSTanakaYDiscontinuation of infliximab in rheumatoid arthritis patients in clinical remissionMod Rheumatol200818546046418535759
   PubMed Web of Science ®Google Scholar
• den BroederAACreemersMCWvan GestelAMvanRielPLCMDose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-αRheumatology200241663864212048289
   PubMed Web of Science ®Google Scholar
• LeeSHLeeYAHongSJYangHIEtanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patientsClin Rheumatol200827217918117874173
   PubMed Web of Science ®Google Scholar
• Navarro-CompánVMoreiraVAriza-ArizaRHernández-CruzBVargas-LebrónCNavarro-SarabiaFLow doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the diseaseClin Rheumatol201130799399621373780
   PubMed Web of Science ®Google Scholar